Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



November 01, 2022

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra, India.

NSE Code: SUNPHARMA

BSE Limited

Market Operations Dept. P. J. Towers, Dalal Street, Mumbai – 400 001, Maharashtra, India.

BSE Code: 524715

Dear Sir/ Madam,

Subject - Outcome of the Board Meeting held today i.e. November 01, 2022

With reference to the intimation of Board meeting submitted on October 10, 2022, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. November 01, 2022 which commenced at 10:10 am and ended at 01:10 pm. The Board has, inter-alia,

1. Approved Financial Results for the quarter and half year ended September 30, 2022

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company and its subsidiaries for the quarter and half year ended September 30, 2022, along with the Limited Review Reports thereon, which are annexed as **Annexure A.**

2. Approved and recommended Appointment of Independent Director

The Board of Directors approved the appointment of Mr. Sanjay Asher (DIN: 00008221), as an Additional Director designated as an Independent Director of the Company for a term commencing from November 01, 2022 till March 31, 2025, subject to approval of the shareholders.

Brief profile of Mr. Sanjay Asher is enclosed. Mr. Asher is not related to any Director of the Company. Further, Mr. Asher, is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

This is for your information and dissemination.

Thank You.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary & Compliance Officer

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.



Brief profile of Mr. Sanjay Asher

Mr. Sanjay Asher is presently a Senior Partner with M/s. Crawford Bayley & Co., which is India's oldest law firm, established in 1830.

Mr. Asher holds a Bachelor's Degree in Commerce and a Bachelor's Degree in Law from the University of Bombay. He has been a practicing Advocate since 1991, and was admitted as a Solicitor in the year 1993. He is also a qualified Chartered Accountant.

He specialises in the fields of M&A, cross border M&A, joint ventures, private equity and capital markets.

He has been a noted speaker at various seminars and conferences including those organised by Institute of Chartered Accountants of India, Institute of Company Secretaries of India.

He has authored several publication published in national and international publications including authored a book on Companies Act, 2013 which was published by CCH, a Wolters Kluwer publication.



12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India

Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Sun Pharmaceutical Industries Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharmaceutical Industries Limited (the "Company") for the quarter ended September 30, 2022 and year to date from April 01, 2022 to September 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

[This space is intentionally left blank]



SRBC&COLLP

Chartered Accountants

Sun Pharmaceutical Industries Limited Limited Review report for the quarter September 30, 2022 Page 2 of 2

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SRBC&COLLP

Chartered Accountants

ICANFirm registration number: 324982E/E300003

per Paul Alvares

Partner

Membership No.: 105754

UDIN: 22105754BBPHU07254

Mumbai

November 01, 2022

Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara. 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended September 30, 2022

(₹ in Million)

Particulars	Quarter ended			Half Year Encled		Year ended	
Particulars	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022	
The second secon	Unaudited	Unaudited	Unaudited	Unaudited	Urnaudited	Audited	
Revenue from operations	1						
a. Revenue from contracts with customers	51,817.2	48.621.6	41,209.3	100,438.8	77,728.1	155,185.0	
b. Other operating revenues	1,035.7	707.2	222.2	1,742.9	356.3	674.8	
Total revenue from operations (I)	52,852.9	49,328.8	41,431.5	102,181.7	78,084.4	155,859.8	
I Other income	417.1	489.9	2,842.7	907.0	3,522.8	9,579.2	
II Total income (I+II)	53,270.0	49,818.7	44,274.2	103,088.7	81,607.2		
V Expenses	3 3,21 616	10,010	77,274.2	100,000.7	01,007.2	165,439.0	
Cost of materials consumed	13,974.9	13,295.2	10.923.0	27,270.1	21,716.8	45,849.7	
Purchases of stock-in-trade	3,186.5	2,779.4	2.854.4	5,965.9	6,854.4	12,486.0	
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(805.2)	(151.1)	484.2	(956.3)	(79.5)	(1,831.6	
Employee benefits expense	5,135.7	5,880.9	5,090.7	11,016.6	10.010.5	20,007.8	
Finance costs	927.7	870.7	1,039.8	1,798.4	2,114.4	3,881.0	
Depreciation and amortisation expense	3,839.5	3,745.0	3,336.4	7,584.5	6,405.7	13,499.5	
Other expenses	13,945.5	14,300.0	12,908.3	28,245.5	27,977.9	52,662.5	
Net (gain) / loss on foreign currency transactions	783.8	(1,272.2)	528.2	(488.4)	(908.6)	(2,389.6	
Total expenses (IV)	40,988.4	39,447.9	37,165.0	80,436.3	74,091.6	144,165.1	
V Profit / (loss) before exceptional item and tax (III-IV)	12,281.6	10,370.8	7,109.2	22,652.4	7,515.6	21,273.9	
VI Exceptional items (Refer Note 3)	1	,	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	22,002.4	1,655.7	18,205.3	
VII Profit / (loss) before tax (V-VI)	12,281.6	10,370.8	7,109.2	22,652.4	307 200 200 200		
VIII (i) Tax expense / (credit)	151.5	252.8	(981.5)	404.3	5,859.9	3,068.6	
(ii) Tax expense - Exceptional (Refer Note 3)	131.3	232.0	(901.5)	404.3	(848.0)	(337.5	
X Profit / (loss) for the period (VII-VIII)	10.100.1	40.440.0			(*)	4,406.0	
	12,130.1	10,118.0	8,090.7	22,248.1	6,707.9	(999.9	
C Other comprehensive income (OCI)				7.070.000.000	111111111111111111111111111111111111111		
a. (i) Items that will not be reclassified to profit or loss	139.7	110.1	(207.9)	249.8	(552.6)	10.5	
(ii) Income tax relating to items that will not be reclassified to profit or loss	(48.8)	(38.5)	48.4	(87.3)	49.8	57.3	
 b. (i) Items that may be reclassified to profit or loss (ii) Income tax relating to items that may be reclassified to profit or loss 	(459.2)	(782.8)	183.6	(1,242.0)	568.3	(396.9	
Total other comprehensive income (a+b) (X)	160.5	273.5	(1,035.5)	434.0	(909.0)	(587.1	
Total comprehensive income for the period (IX+X)	(207.8)	(437.7)	(1,011.4)		(843.5)	(916.2	
(II Paid-up equity share capital - face value ₹1 each	11,922.3	9,680.3	7,079.3	21,602.6	5,864.4	(1,916.1	
CIII Other equity	2,399.3	2,399.3	2,399.3	2,399.3	2,399.3	2,399.3	
(IV Earnings per equity share of ₹ 1 each (not annualised for quarters)						243,480.2	
₹ (Basic)	5.1	4.2	3.4	9.3	2.8	(0.4	
₹ (Diluted)	5.1	4.2	3.4	9.3	2.8	(0.4	
See accompanying notes to the unaudited standalone financial results				3.0	2.0	(0.4	
Research and development expenses incurred (included above)	4,489.9	3,238.8	4,088.3	7,728.7	8,450.4	10 104	
	1,100.0	0,200.0	4,000.3	7,720.7	0,450.4	16,104.	

Notes:

- 1 The above unaudited standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 01, 2022.
- 2 The above unaudited standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3 Exceptional items includes (Refer financial results of respective period for detailed information):
 - a) Results for the half year ended September 30, 2021 and year ended March 31, 2022 include a charge of ₹ 1,655.7 Million towards impairment of an acquired intangible asset under development.
 b) Results for the year ended March 31, 2022 includes a charge of USD 210 Million along with its related legal charges of USD 8.3 Million (equivalent to ₹ 16,549.6 Million inclusive legal charges) towards settlement of alleged violation of antitrust laws.
 - c) Consequent to the settlement mentioned in 3(b) above, during the year ended March 31, 2022, the Company had written off MAT credit of ₹ 4,406.0 Million and disclosed the charge as an exceptional item.
- As part of the ongoing simplification of the group structure in India, the Board of Directors of the Company at its meeting held on May 30, 2022, approved the Scheme of Amalgamation for the merger of Wholly-owned Subsidiaries, Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited (collectively "Transferor Companies"), with Sun Pharmaceutical Industries Limited ("Transferee Company") with an appointed date of April 01, 2022 and / or such other date as may be approved by the National Company Law Tribunal pursuant to the provisions of Sections 230 to 232 of Companies Act, 2013 and other relevant provisions of the Companies Act, 2013 and
- 5 The Company has only one reportable segment namely "Pharmaceuticals".
- 6 Figures for previous periods have been regrouped / reclassified wherever considered necessary.

SIGNED FOR IDENTIFICATION BY

Mumbai, November 01, 2022

SRBC&COLLP MUMBAI MUMBAI SES

For and on behalf of the Board

Dilip S. Shanghvi Managing Director

Sun Pharmaceutical Industries Limited
Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.
Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063
Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Unaudited Standalone Statement of Assets and Liabilities

ASSETS (1) Non-current assets (a) Property, plant and equipment (b) Capital work-in-progress (c) Goodwill (d) Capital work-in-progress (d) Coodwill (e) Capital work-in-progress (e) Capital work-in-progress (f) Coodwill (g) Capital work-in-progress (g) Coodwill (g) Capital work-in-progress (g) Capital work	Particulars	(₹ in Million			
ASSETS (a) Property, plant and equipment (b) Capital work-in-progress (c) Goodwill (d) Other Intangible assets (e) Goodwill (d) Other Intangible assets (e) Interest in the nature of equity in subsidiaries (g) Investments in the nature of equity in subsidiaries (g) Investments in the nature of equity in subsidiaries (g) Investments (ii) Loans (iii) Other financial assets (iii) Uner financial assets (iii) Other financial assets (iii) Index sects (iii) Trade receivables (iii) Cash and cash equivalents (iv) Dans balances other than (iii) above (v) Loans (vi) Other financial assets (iii) Other financial intellities (iii) Other financial intellities (iii) Other equity (iii) Other financial intellities (iii) Other financial intellit	raticulais				
(a) Property, plant and equipment (b) Capital work-in-progress (c) Goodwill (c) Capital work-in-progress (d) Goodwill (c) Capital work-in-progress (e) Goodwill (c) Capital work-in-progress (e) Goodwill (c) Capital (c) Capi	ASSETS	Unaudited	Audited		
(b) Capital work-in-progress (c) Goodwill (1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,2	(1) Non-current assets				
(b) Capital work-in-progress (c) Goodwill (1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,2	(a) Property, plant and equipment	48 408 3	49 695		
(c) Godwill (1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 1,208.0 (2) Other Intangible assets under development (5) Interstments in the nature of equity in subsidiaries (5) Investments in the nature of equity in subsidiaries (1) Investments in the nature of equity in subsidiaries (1) Investments (2, 2, 66.7 2, 350 1, 2, 350 1, 2, 350 1, 2, 350 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 3, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1, 30 1					
(d) Other Intangible assets (e) Intangible assets (1,971.2 de,224 (6) Intangible assets under development (5) Introduced assets (5) Introduced assets (7) Investments in the nature of equity in subsidiaries (7) Investments (8) Inventories (8) Investments (8) Investments (8) Investments (9) Investments (9) Investments (9) Investments (10) Investment (
(e) Intangible assets under development (f) Investments in the nature of equity in subsidiaries (g) Financial assets (15),395.2 (15),404 (g) Financial assets (10) Investments (10) Investments (10) Investments (10) Investments (10) Income tax assets (Net) (10) Income tax assets (10)					
(f) Investments in the nature of equity in subsidiaries (g) Financial assets (g) Financial assets (ii) Loans (iii) Other financial assets (f) Investments (iii) Coans (iiii) Other financial assets (financial ass					
(g) Financial assets (i) Investments (ii) Coars (iii) Other financial assets (iii) Coher financial assets (iii) Coher financial assets (iii) Coher financial assets (iv) Deferred tax assets (Net) (i) Cher non-current assets (i) Cher non-current assets (i) Cher non-current assets (ii) Cassets (a) Inventories (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iii) Cash and cash equivalents (iv) V Loans (
(i) Investments (ii) Loans (iii) Other financial assets (iiii) Other financial assets (iiii) Other financial assets (iiii) Other financial assets (iv) Deferred tax assets (Net) (iv) Income tax assets (Net) (iv) Income tax assets (iv) G.566.7 (iv) Other non-current assets (iv) Financial assets (iv) Investments (iv) Financial assets (iv) Bank balances other than (iii) above (iv) Loans (iv) Other financial assets (iv) Other financial idabilities (iv) Other financ		153,395.2	153,404.		
(ii) Loans (iii) Other financial assets (iii) Other financial assets (iii) Other financial assets (iv) Deferred tax assets (Net) (i) Income tax assets (Net) (i) Other on-current assets (i) Other non-current assets (iii) Cash and cash equivalents (iv) Loans (iv) Lo		2200			
(iii) Other financial assets (het) 6,903.7 3,244 (h) Income tax assets (Net) 6,903.7 3,244 (i) Income tax assets (Net) 6,903.7 3,244 (i) Income tax assets (Net) 6,164.3 8,836 (i) Other non-current assets 2,566.7 2,350 (ii) Cher non-current assets 309,270.8 310,617 (iv) Cher non-current assets 309,270.8 310,617 (iv) Cher non-current assets 309,270.8 310,617 (iii) Cher non-current assets (iii) Inventories 37,370.2 34,037 (iii) Trade receivables 63,681.0 42,451 (iii) Cash and cash equivalents 2,688.8 4,195 (iv) Bank balances other than (iii) above 841.2 1,154 (iv) Chars 93.9 (iv) Other financial assets 4,933.1 4,021 (iv) Other current assets 9,371.9 9,155 (iv) Other current assets 1118,980.1 97,037 (iv) Other current as			154		
(h) Deferred tax assets (Net) (i) Income tax assets (Net) (i) Income tax assets (Net) (i) Cher non-current assets (ii) Cher non-current assets (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Dank balances other than (iii) above (iv) Loans (iv) Cher financial assets (iv) Dank balances other than (iii) above (iv) Loans (iv) Cher financial assets (iv) Dank balances other than (iii) above (iv) Loans (iv) Cher financial assets (iv) Dank balances other than (iii) above (iv) Cher financial assets (iv) Loans (iv) Cher equiv (iv)	THE STATE OF THE S	39,301.9	36,566		
(i) Income tax assets (Net) (j) Other non-current assets (a) Inventories (a) Inventories (b) Financial assets (i) Investments (ii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Ioans (v) Other financial assets (i) Other requires (iii) Cash and cash equivalents (iv) Dans balances other than (iii) above (v) Loans (vi) Other financial assets (vi) Other financial assets (iii) Cash and cash equivalents (iv) Other financial assets (vi) Other financial assets (vi) Other financial assets (vi) Other financial assets (iii) Cash and cash equivalents (iii) Other financial assets (iii) Cash and cash equivalents (iii) Other financial assets (iii) Other financial assets (iii) Cash and cash equivalents (iii) Other financial assets (iii) Cash and cash equivalents (iii) Other financial assets (iii) Cash and cash equivalents (iii) Other equity (iv) Other equity (i		602.0	651		
(i) Other non-current assets Total non-current assets (2) Current assets (3) 10,9270.8 310,617 (2) Current assets (3) Inventories (5) Financial assets (6) Investments (7) Trade receivables (8) Investments (9) Trade receivables (10) Cash and cash equivalents (10) Cash and cash equivalents (10) Cash and cash equivalents (10) Loans (10) Cash and cash equivalents (10) Loans (10) Cash cash cash equivalents (10) Loans (10) Cash cash cash equivalents (10) Loans (10) Cash cash cash equivalents (11) Cash cash cash equivalents (11) Cash cash cash equivalents (12) Cash cash cash equivalents (13) Cash cash cash equivalents (14) Cash cash cash equivalents (15) Cash cash cash equivalents (16) Cash cash cash equivalents (17) Cash cash cash equivalents (18) Cash cash cash equivalents (19) Cash cash cash equivalents (19) Cash cash cash equivalents (10) Cash cash cash equivalents (11) Cash cash cash equivalents (12) Cash cash cash equivalents (13) Cash cash cash equivalents (14) Cash cash cash equivalents (15) Cash cash cash equivalents (16) Cash cash cash equivalents (17) Cash cash cash equivalents (18) Cash cash cash equivalents (19) Cash cash cash cash equivalents (19) Cash cash cash cash cash equivalents (19) Cash cash cash cash cash cash cash cash c		6,903.7	3,240		
(i) Other non-current assets Total non-current assets (2) Current assets (a) inventories (b) Financial assets (ii) Trade receivables (iii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iv) Loans (v) Loans (vi) Other financial assets (vi) Loans (vi) Other financial assets (vii) Loans (viii) Citer financial assets (viii) Loans (viii) Citer financial assets (viiii) Loans (viiii) Citer financial assets (viiii) Loans (viiii) Citer financial assets (viiii) Loans (viiiii) Loans (viiii) Loans (viiiii) Loans (viiiii) Loans (viiiiii) Loans (viiiiiii) Loans (viiiiii) Loans (viiiiii) Loans (viiiii) Loans (viiiii) Loans (viiiiii) Loans (viiiiii) Loans (viiiii) Loans (viiiii) Loans (viiiii) Loans (viiiii) Loans (viiiiii) Loans (viiiii) Loans (viiiii) Loans (viiiii) Loans (viiiii) Loans (viiiii) Loans (viiii) Loans (viiiii) Loans (viiii) Loans (viiiii) Loans (viiii) Loans (viiiii) Loans (viiiiii) Loans (viiiiiii) Loans (viiiii) Loans (viiiii) Loans (viiiiii) Loans (viiiiii) L		6,164.3			
Total non-current assets 309,270.8 310,617	(j) Other non-current assets				
(a) Inventories 37,370.2 34,037 (b) Financial assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Loans (v) Uncent assets (v) Bank balances other than (iii) above (v) Loans (v) Cother current assets (c) Other current assets (d) Borrowings (d) Equity AND LIABILITIES Equity (a) Equity share capital (b) Other equity (c) Other equity (d) Equity Share capital (e) Financial liabilities (i) Borrowings (ii) Lease liabilities (ii) Provisions (c) Provisions (a) Financial liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions (a) Financial liabilities (ii) Lease liabilities (iii) Cother current liabilities (iii) Lease liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv)	Total non-current assets		310,617		
(a) Inventories 37,370.2 34,037 (b) Financial assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Loans (v) Uncent assets (v) Bank balances other than (iii) above (v) Loans (v) Cother current assets (c) Other current assets (d) Borrowings (d) Equity AND LIABILITIES Equity (a) Equity share capital (b) Other equity (c) Other equity (d) Equity Share capital (e) Financial liabilities (i) Borrowings (ii) Lease liabilities (ii) Provisions (c) Provisions (a) Financial liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions (a) Financial liabilities (ii) Lease liabilities (iii) Cother current liabilities (iii) Lease liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv)	(2) Current assets				
(b) Financial assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Dank balances other than (iii) above (v) Loans (vi) Cher financial assets (vi) Dank balances other than (iii) above (vi) Cither financial assets (vi) Cither current assets (c) Other current assets (d) Total current assets (e) Total current assets (f) Equity AND LIABILITIES (f) Cither equity (g) Equity Share capital (g) Other equity (g) Equity Share capital (g) Financial liabilities (g) Borrowings (g) Leas liabilities (g) Current liabilities (g) Financial liabilities (h) Fina		07.070.0			
(i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Other financial assets (v) Loans (vi) Other financial assets (c) Other current assets (d) Joans (e) Other current assets (e) Other current liabilities (f) Other equity (g) Equity AND LIABILITIES Equity (a) Equity share capital (b) Other equity (c) Other equity (d) Equity (e) Equity (a) Equity share capital (b) Other equity (c) Equity (c) Equity (d) Equity (e) Equity (e) Equity (e) Equity (f) Non-current liabilities (g) Borrowings (g) Lease liabilities (g) Provisions (g) Provisions (g) Provisions (g) Financial liabilities (g) Borrowings (g) From the current liabilities (g) Borrowings (g) Other current liabilities (g) Borrowings (g) Other current liabilities (h) Other curr		37,370.2	34,037		
(ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iv) Loans (vi) Other financial assets (vi) Other financial assets (c) Other current assets Total current assets EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (i) Borrowings (ii) Lease liabilities (i) Borrowings (ii) Trade payables (a) Iotal outstanding dues of micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (iv) Other current liabilities (iv) Other current liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other current					
(iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (iv) Cans (iv) Cons (iv) Other financial assets (v) Loans (vi) Other financial assets (vi) Other financial assets (vi) Other current assets (viii) Other current assets (viii) Other current assets (viiii) Other current assets (viiii) Cash and Cash assets (viiiii) Cash and Cash assets (viiii) Cash assets (viiii) Cash and Cash assets (viiiii) Cash assets (viiii) Cash assets (viiiii) Cash assets (viiiii) Cash assets (viiiii) Cash assets (viiiii) Cash assets (viiii) Cash assets (viiiii) Cash assets (viiiii) Cash assets (viiiiii) Cash assets (viiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii			1,930		
(iv) Bank balances other than (iii) above (y) Loans (9.3.9) 91 91 (vi) Other financial assets (4.933.1) 4.021 (c) Other current assets (9.371.9) 9.155 Total current assets (9.371.9) 9.155 Total current assets (9.371.9) 9.155 (118,980.1) 97,037 TOTAL ASSETS (428,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (28,250.9) 407,654 (2			42,451		
(iv) Chars (vi) Other financial assets (2) 0 ther current assets (3,371.9		2,688.8	4,195		
(v) Loans (vi) Other financial assets (vi) Other current assets (c) Other current assets (d) Other current assets (e) Other current assets (f) Other current assets (f) Other current assets (g) Other current assets (h) Other current assets (h) Other current assets (h) Other current liabilities (h) Other equity ((iv) Bank balances other than (iii) above		1.154		
(vi) Other financial assets (c) Other current assets (c) Other current assets (d) 3,371.9 (d) 9,155 Total current assets (d) 118,980.1 (e) 7,035 TOTAL ASSETS (e) 428,250.9 (e) 407,654 EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity (c) Equity (d) Equity share capital (e) Financial liabilities (e) Financial liabilities (i) Borrowings (ii) Lease liabilities (i) Other non-current liabilities (ii) Corrowings (iii) Lease liabilities (c) Provisions (d) Financial liabilities (e) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Lease liabilities (iii) Corrowings (iii) Lease liabilities (i) Borrowings (iii) Trade payables (iii) Lease liabilities (i) Borrowings (iii) Lease liabilities (i) Borrowings (ii) Trade payables (iii) Lease liabilities (i) Dortowings (iii) Lease liabilities (iiii) Lease liabilities (iiii) Lease liabilities (iiii) Lease liabi	(v) Loans	93.9	91		
(c) Other current assets Total current assets Total current assets Total current assets Total current assets Total current assets ### 118,980.1 ### 20,037 ### 20,037 ### 20,037 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 ### 20,038 #	(vi) Other financial assets	The second of th			
Total current assets	(c) Other current assets				
### TOTAL ASSETS #### EQUITY AND LIABILITIES #### Equity ### (a) Equity share capital ### (b) Other equity ### (D) Other equity ### (a) Equation of Equati	Total current assets				
EQUITY AND LIABILITIES Equity (a) Equity share capital 2,399.3 2,399 (b) Other equity 257,884.8 243,480 Total equity 260,284.1 245,879 Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings 5,162.8 48,656 (ii) Lease liabilities 1,855.9 1,896 (b) Other non-current liabilities 5,346.3 6,187 (c) Provisions 2,014.2 3,976 Total non-current liabilities (a) Financial liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) Financial liabilities (ii) Borrowings (iii) Trade payables (a) total outstanding dues of micro and small enterprises (iii) Lease liabilities (iii) Lease liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions 194.0 156 (iv) Other financial liabilities (iv) Other current liabilities (iv) Other financial liabilities (iv) Other finan		110,000.1	57,057		
Equity	TOTAL ASSETS	428,250.9	407,654		
(a) Equity share capital (b) Other equity Total equity Cotal equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (a) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (iv) Other financial liabilities (iv) Other current liabilities (i	EQUITY AND LIABILITIES				
(b) Other equity Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (b) Borrowings (c) Provisions (a) Italiabilities (b) Other payables (a) total outstanding dues of micro and small enterprises (a) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total liabilities Total liabilities 167,966.8 161,775					
Total equity 260,284.1 245,879		2,399.3	2,399		
Total equity 260,284.1 245,879		257,884.8	243,480		
(a) Financial liabilities (i) Borrowings 59,162.8 48,656 (ii) Lease liabilities 1,855.9 1,896 (b) Other non-current liabilities 5,346.3 6,187 (c) Provisions 2,014.2 3,976 Total non-current liabilities 68,379.2 60,717 (2) Current liabilities (a) Financial liabilities (i) Borrowings 129.5 30 (ii) Trade payables (a) total outstanding dues of micro and small enterprises (a) total outstanding dues of creditors other than micro and small anterprises (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 54,073.7 40,678 (c) Provisions 8,732.4 25,628 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,778	Total equity	260,284.1	245,879		
(a) Financial liabilities (i) Borrowings (ii) Lease liabilities (b) Other non-current liabilities (c) Provisions (d) Provisions (e) Provisions (e) Provisions (f) Edition on current liabilities (f) Edition on current liabilities (g) Financial liabilities (g) Financial liabilities (g) Financial liabilities (g) Borrowings (g) Trade payables (g) Ital outstanding dues of micro and small enterprises (g) Ital outstanding dues of creditors other than micro and small enterprises (g) Lease liabilities (g) Other financial liabilities (g) Other current liabilities (g) Provisions (g	Liabilities				
(a) Financial liabilities (i) Borrowings (ii) Lease liabilities (b) Other non-current liabilities (c) Provisions (d) Provisions (e) Provisions (e) Provisions (f) Edition on current liabilities (f) Edition on current liabilities (g) Financial liabilities (g) Financial liabilities (g) Financial liabilities (g) Borrowings (g) Trade payables (g) Ital outstanding dues of micro and small enterprises (g) Ital outstanding dues of creditors other than micro and small enterprises (g) Lease liabilities (g) Other financial liabilities (g) Other current liabilities (g) Provisions (g	(1) Non-current liabilities				
(i) Borrowings (ii) Lease liabilities (iii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities Total current liabilities 194,0 156 15,154,7 1,463 16,775 Total current liabilities 167,966.8 161,775					
(ii) Lease liabilities		50 400 0	40.000		
(b) Other non-current liabilities					
(c) Provisions Total non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities Total liabilities (c) Provisions Total liabilities (d) Provisions Total liabilities (e) Provisions Total liabilities (f) Provisions Total liabilities (h) Other current liabilities					
Total non-current liabilities 68,379.2 60,717 (2) Current liabilities (a) Financial liabilities (i) Borrowings 129.5 30 (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,628 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities				
(2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities Total liabilities (a) 129.5 (1068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 (1,068.3 ((ii) Lease liabilities (b) Other non-current liabilities	5,346.3			
(a) Financial liabilities 129.5 30 (i) Borrowings 129.5 30 (ii) Trade payables 1,068.3 1,052 (a) total outstanding dues of micro and small enterprises 30,235.0 26,051 (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,056 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions	5,346.3 2,014.2	6,187 3,976		
(i) Borrowings 129.5 30 (ii) Trade payables 1,068.3 1,052 (a) total outstanding dues of micro and small enterprises 30,235.0 26,051 (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,056 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions	5,346.3 2,014.2	3,976		
(iii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities Total liabilities (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (c) Provisions (d) Provisions (e) Provisions (iv) Other current liabilities (iv) Other c	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities	5,346.3 2,014.2	3,976		
(iii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities Total liabilities (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (c) Provisions (d) Provisions (e) Provisions (iv) Other current liabilities (iv) Other c	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities	5,346.3 2,014.2	3,976		
(a) total outstanding dues of micro and small enterprises 1,068.3 1,052 (b) total outstanding dues of creditors other than micro and small enterprises 30,235.0 26,051 (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities	5,346.3 2,014.2 68,379.2	3,976 60,717		
(b) total outstanding dues of creditors other than micro and small enterprises 30,235.0 26,051 (iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings	5,346.3 2,014.2 68,379.2	3,976 60,717		
enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total liabilities 194.0 156 54,073.7 40,678 5,154.7 7,463 8,732.4 25,628 101,058 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables	5,346.3 2,014.2 68,379.2	3,976 60,717		
(iii) Lease liabilities 194.0 156 (iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises	5,346.3 2,014.2 68,379.2 129.5 1,068.3	3,976 60,717 30 1,052		
(iv) Other financial liabilities 54,073.7 40,678 (b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,628 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small	5,346.3 2,014.2 68,379.2 129.5 1,068.3	3,976 60,717 30 1,052		
(b) Other current liabilities 5,154.7 7,463 (c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0	3,976 60,717 30 1,052 26,051		
(c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,056 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0	3,976 60,717 30 1,052 26,051		
(c) Provisions 8,732.4 25,625 Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0	3,976 60,717 30 1,052 26,051		
Total current liabilities 99,587.6 101,058 Total liabilities 167,966.8 161,775	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0 54,073.7	3,976 60,717 30 1,052 26,051 156 40,678		
TOTAL FOLLOW AND ALLOW THE TOTAL FOLLOW TO THE TOTAL FOLLOW THE FOLLOW THE TOTAL FOLLOW THE FO	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0 54,073.7 5,154.7	3,976 60,717 30 1,052 26,051 156 40,678 7,463		
	(ii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0 54,073.7 5,154.7 8,732.4			
	(iii) Lease liabilities (b) Other non-current liabilities (c) Provisions Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables (a) total outstanding dues of micro and small enterprises (b) total outstanding dues of creditors other than micro and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions Total current liabilities	5,346.3 2,014.2 68,379.2 129.5 1,068.3 30,235.0 194.0 54,073.7 5,154.7 8,732.4 99,587.6	3,976 60,717 30 1,052 26,051 156 40,678 7,463 25,625 101,058		

SIGNED FOR IDENTIFICATION BY HS SRBC&COLLP MUMBAI



Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Unaudited Standalone Cash Flow Statement for the half year ended September 30, 2022

(₹ in Million)

		(₹ in Million)
Particulars	Half year ended	Half year ended
	30.09.2022	30.09.2021
	Unaudited	Unaudited
A. Cash flow from operating activities		
Profit / (loss) before tax	22,652.4	5,859.9
Adjustments for:		,
Depreciation and amortisation expense	7,584.5	6,405.7
Net (gain) / loss on sale/write off /impairment of property, plant and equipment, other intangible assets	(22.3)	1,755.7
and intangible assets under development		
Finance costs	1,798.4	2,114.4
Interest income	(608.8)	(1,373.4)
Net (gain) / loss arising on financial assets measured at fair value through profit or loss	(000.0)	1,000,000,000,000,000,000,000,000,000,0
Net (gain) / loss on sale of financial assets measured at fair value through profit or loss	(57.1)	(0.2)
Net (gain) / loss on sale of financial assets measured at fair value through other comprehensive income	(37.1)	(241.9)
(Gain) / loss on sale / dissolution of subsidiary	0.0	(57.7)
Provision / write off / (reversal) for doubtful trade receivables / advances	8.8	
Sundry balances written back, net	(26.8)	(17.1)
Effect of exchange rate changes	(120.1)	(16.8)
Operating profit / (loss) before working capital changes	(511.6)	(1,508.7)
Operating profit? (1035) before working capital changes	30,697.4	12,919.9
Movements in working capital:	1	
(Increase)/ decrease in inventories	(0.000.0)	4 9 9 9
(Increase)/ decrease in trade receivables	(3,332.8)	1,168.2
(Increase)/ decrease in other assets	(18,705.2)	7,311.6
Increase / (decrease) in trade payables	(1,716.1)	2,722.9
Increase / (decrease) in other liabilities	5,149.0	(11,938.3)
Increase / (decrease) in provisions	4,873.2	1,102.7
Cash generated / (used in) from operations	(18,573.4)	(2,259.1)
Net Income tax (paid) / refund received (including interest on refunds)	(1,607.9)	11,027.9
Net cash generated from / (used in) operating activities (A)	(1,016.7)	(584.0)
general general warms (and my operating activities (A)	(2,624.6)	10,443.9
B. Cash flow from investing activities		
Payments for purchase of property, plant and equipment (including capital work-in-progress, other	/F F70 0\	(0.407.0)
intangible assets and intangible assets under development)	(5,579.0)	(6,437.0)
Proceeds from disposal of property, plant and equipment and other intangible assets	40.0	
Loans / Inter corporate deposits given / placed	46.3	54.3
Loans / Inter corporate deposits received back / matured	(159.2)	
Purchase of investments	60.0	8,069.0
Proceeds from sale of investments	(13,699.3)	(43,033.2)
Bank balances not considered as cash and cash equivalents	15,686.9	46,610.7
Fixed deposits/ margin money placed	(0.0)	
Fixed deposits/ margin money matured	(0.9)	(10.0)
Interest received	1,000.0	-
Net cash from / (used in) investing activities (B)	(2,141.6)	102.8
(2)	(2,141.0)	5,356.6
C. Cash flow from financing activities		t :
Proceeds / (repayment) of borrowings and working capital loans (net)	10,605.2	(1,374.1)
Repayment towards lease liabilities	(170.1)	(206.9)
Finance costs	(10.1)	(196.6)
Dividend paid	(7,193.8)	(4,812.1)
Net cash from / (used in) financing activities (C)	3,231.2	(6,589.7)
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(1,535.0)	9,210.8
Cash and cash equivalents at the beginning of the period	4,195.3	3,510.6
	7,100.0	0,010.0
Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end of the period	28.5	58.4







12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India

Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Sun Pharmaceutical Industries Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sun Pharmaceutical Industries Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associates and joint venture for the quarter ended September 30, 2022 and year to date from April 01, 2022 to September 30, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Holding Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

- 4. The Statement includes the unaudited financial results of the entities mentioned in Annexure I to the Statement.
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under

SRBC&COLLP

Chartered Accountants

Sun Pharmaceutical Industries Limited Limited Review report for the quarter ended September 30, 2022 Page 2 of 4

Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of 19 subsidiaries including its associates, whose financial results and other financial information without giving effect to the elimination of intragroup transactions reflect, Group's share of total assets of INR 5,25,926.6 Million as at September 30, 2022, total revenue of INR 34,229.5 Million and INR 66,644.2 Million, total net profit after tax of INR 2,202.3 million and INR 5,271.4 Million, total comprehensive income of INR 1,366.4 Million and INR 3,235.1 Million, for the guarter ended September 30, 2022 and half year ended on that date respectively, and net cash inflows of INR 1,056.1 Million for the period from April 01, 2022 to September 30, 2022, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on interim financial results and other financial information of these entities have been furnished to us by management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associates is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

8

For S R B C & CO LLP Chartered Accountants

-ICAL Firm registration number: 324982E/E300003

per Paul Alvares

Partner

Membership No.: 105754

UDIN: XX105754BBPHVF2129

Mumbai

November 01, 2022


SRBC&COLLP

Chartered Accountants

Sun Pharmaceutical Industries Limited Limited Review report for the quarter ended September 30, 2022 Page 3 of 4

Annexure I - List of entities included in the report on the Consolidated Financial Results

Sr.No	Name of the entity
	Subsidiaries:
1	Sun Pharma France (formerly known as Ranbaxy Pharmacie Generiques)
2	Zenotech Laboratories Limited (consolidated)
3	Sun Pharma (U.K.) Limited (formerly known as Ranbaxy (U.K.) Limited)
4	Sun Pharma Holdings (U.K.) Limited (Formerly known as Ranbaxy Holdings (U.K.) Limited)
5	Basics GmbH
6	Sun Pharma Laboratories S.L.U (formerly known as Laboratories Ranbaxy, S.L.U.)
7	Sun Pharma Italia SRL (formerly known as Ranbaxy Italia Spa)
8	Sun Pharma (Netherlands) B.V.
9	Ranbaxy (Poland) SP. Z O.O.
10	AO Ranbaxy
11	"Ranbaxy Pharmaceuticals Ukraine" LLC
12	Terapia SA
13	Ranbaxy South Africa (Pty) Ltd (consolidated)
14	Ranbaxy Nigeria Limited
15	Ranbaxy Pharmaceuticals (Pty) Ltd
16	Sun Pharmaceuticals Morocco LLC
17	Sun Pharma Egypt Limited LLC
18	Rexcel Egypt LLC
19	Ranbaxy (Malaysia) SDN. BHD.
20	Sun Pharma ANZ Pty Ltd
21	Sun Pharmaceuticals Holdings USA, Inc. (consolidated)
22	Ranbaxy Farmaceutica Ltda.
23	Sun Pharmaceutical Peru S.A.C.
24	Sun Pharma Canada Inc.
25	Ranbaxy (Thailand) Co., Ltd.
26	JSC Biosintez
27	Faststone Mercantile Company Private Limited
28	Green Eco Development Centre Limited
29	Neetnav Real Estate Private Limited
30	Realstone Multitrade Private Limited
31	Skisen Labs Private Limited
32	Softdeal Pharmaceuticals Private Limited (formerly known as Softdeal Trading Company Private Limited)
33	Universal Enterprises Private Limited
34	Sun Pharmaceutical (Bangladesh) Limited
35	Sun Pharmaceuticals Germany GmbH
36	Sun Pharma Switzerland Ltd.



Sun Pharmaceutical Industries Limited Limited Review report for the quarter ended September 30, 2022 Page 4 of 4

Sr.No	Name of the entity
37	Sun Pharmaceutical Industries (Europe) B.V.
38	000 "Sun Pharmaceutical Industries" Limited (liquidated w.e.f. 23 rd May 2022)
39	Alkaloida Chemical Company Zrt.
40	Sun Pharmaceuticals SA (Pty) Ltd
41	Sun Pharma Holdings
42	Aditya Acquisition Company Ltd.
43	Taro Pharmaceutical Industries Ltd (TARO) (consolidated)
44	Sun Laboratories FZE
45	Sun Pharma East Africa Limited
46	Sun Pharma Philippines, Inc.
47	Sun Pharma Japan Ltd. (consolidated)
48	Sun Pharmaceutical Industries (Australia) Pty Limited
49	Sun Farmaceutica do Brasil Ltda.
50	Sun Pharmaceutical Industries S.A.C.
51	Sun Pharma De Mexico S.A. DE C.V.
52	Sun Pharma De Venezuela, C.A.
53	Sun Pharma Laboratories Limited
54	Sun Pharmaceutical Medicare Limited
55	Caraco Pharmaceuticals Private Limited
56	Sun Pharma Distributors Limited
57	Realstone Infra Limited
58	Sun Pharma Shanghai Limited
59	Sun Pharmaceuticals EZ Limited
	Joint Venture:
1	Artes Biotechnology GmbH
	Associates:
1	Medinstill LLC (Consolidated)
2	Generic Solar Power LLP
3	Trumpcard Advisors and Finvest LLP
4	Tarsier Pharma Limited (formerly known as Tarsius Pharma Ltd.)
5	WRS Bioproducts Pty Limited



Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 432-4 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2022

(₹ In Million)

	. 0	uarter ended		Half Year	behne	Year ende	
Portioularo	30.09.2022	30.06.2022	30.09.2021	LIMBORE INCOMES TO THE PROPERTY.			
Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	Onadanoa	Ondoniou	Onduditod	Onduditod	Officación	riddica	
Revenue from operations							
a. Revenue from contracts with customers	108,091.9	106,439.7	95,567.4	214,531.6	192,261.7	384,264	
b. Other operating revenues	1,430.9	1,177.9	691.9	2,608.8	1,185.0	2,280	
Total revenue from operations (I)	109,522.8	107,617.6	96,259.3	217,140.4	193,446.7	386,544	
I Other income	852.2	21.4	2,228.9	873.6	3,754.1	9,215	
II Total income (I+II)	110,375.0	107,639.0	98,488.2	218,014.0	197,200.8	395,760	
V Expenses	D.L. Market B. Co. P. Co. Co.						
Cost of materials consumed	20,173.4	20,006.0	15,849.4	40,179.4	31,470.4	70,49	
Purchases of stock-in-trade	8,810.5	9,108.3	8,735.8	17,918.8	18,367.2	34,100	
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,903.2)	(112.3)		(2,015.5)	1,875.3	(1,076	
Employee benefits expense	20,045.6	20,748.5	18,062.7	40,794.1	35,650.1	73,00	
Finance costs	193.9	136.9	359.5	330.8	710.4	1,27	
Depreciation and amortisation expense	6,099.5	5,880.0	5,303.7	11,979.5	10,335.9	21,43	
Other expenses	30,416.3	30,479.9	25,915.1	60,896.2	51,608.8	107,58	
Net (gain) / loss on foreign currency transactions	2,414.7	(1,456.7)	-1400 Sept. 10 10 -10 10	958.0	(35.3)		
		84,790.6	75,623.1	171,041.3		7211111	
Total expenses (IV)	86,250.7	5.000 Kr. 201 CO000	FR. 300 F. 300 S. 300 S. 300 S.	A GOVERNMENT OF THE COLOR	149,982.8	305,27	
/ Profit / (loss) before exceptional items and tax (III-IV)	24,124.3	22,848.4	22,865.1	46,972.7	47,218.0	90,48	
/I Exceptional items (Refer Note 4)		00.040.4		40.070.7	6,310.7	45,66	
/II Profit / (loss) before tax (V-VI)	24,124.3	22,848.4	22,865.1	46,972.7	40,907.3	44,81	
/III (i) Tax expense/(credit) for period / year	1,522.6	1,889.9	1,977.8	3,412.5	5,933.5	11,51	
(ii) Tax expense/(credit) - Exceptional (Refer Note 4)			-	40 500 0	-	(76	
X Profit / (loss) for the period before share of profit / (loss) of associates and joint venture (VII-VIII)	22,601.7	20,958.5	20,887.3	43,560.2	34,973.8	34,05	
Share of profit / (loss) of associates and joint venture (net)	(42.7)	(24.6)	(23.9)	(67.3)	(70.0)	(16	
(I Net Profit / (loss) after taxes and share of profit / (loss) of associates and	22,559.0	20,933.9	20,863.4	43,492.9	34,903.8	33,89	
joint venture but before non-controlling interests (IX+X)					*		
Non-controlling interests	(63.2)	325.1	393.3	261.9	(8.0)	1,16	
XII Net Profit / (loss) after taxes, share of profit / (loss) of associates and	22,622.2	20,608.8	20,470.1	43,231.0	34,911.8	32,72	
joint venture and non-controlling interests							
(III Other comprehensive income (OCI)							
A. (i) Items that will not be reclassified to profit or loss	510.0	(331.0	(1,355.7)	179.0	(2,291.4)	(1,87	
(ii) Income tax relating to items that will not be reclassified to profit or loss	(125.1	The state of the s		(129.6	THE RESIDENCE OF THE PARTY OF T	16	
B. (i) Items that may be reclassified to profit or loss	6,662.8	5	0.00			No. of the last of	
(ii) Income tax relating to items that may be reclassified to profit or loss	198.1						
Total other comprehensive income (A+B) (XIII)	7,245.8				- '	5,57	
XIV Total comprehensive income for the period (XI+XIII)	29,804.8			60,183.9		39,46	
Attributable to:			10.3 40.33333			,	
- Owners of the Company	29,096.4	29,168.7	17,492.1	58,265.1	36,091.3	37,5	
- Non-controlling interests	708.4			1,918.8			
A 1 to the American State of Control of Cont	1.2.2.2		1000 - 400 Profession	194 NO. 10 OC. 10			
XV Paid-up equity share capital - face value ₹ 1 each	2,399.3	2,399.3	2,399.3	2,399.3	2,399.3	2,3	
XVI Other equity	_,,						
						477,7	
XVII Earnings per equity share of ₹ 1 each (not annualised for quarters)							
₹ (Basic)	9.4	8.6	8.5	18.0	14.5		
₹ (Diluted)	9.4	8.6	8.5	18.0	14.5		
See accompanying notes to the unaudited consolidated financial results							
Research and development expenses incurred (included above)	5,583.7	7 4,498.3	5,163.7	10,082.0	10,911.8	21,3	






Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012. Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Unaudited Consolidated Statement of Assets and Liabilities

(₹ In Million)

Particulars			
	As at	As at	
	30.09.2022	31.03.2022	
	Unaudited	Audited	
ASSETS			
(1) Non-current assets			
(a) Property, plant and equipment	105,313.2	103,713.8	
(b) Capital work-in-progress	8,057.1	7,975.1	
(c) Goodwill (Net)	70,414.6	65,494.5	
(d) Other intangible assets	53,971.3	55,389.1	
(e) Intangible assets under development	5,775.1	4,892.9	
(f) Investments in associates	2,400.0	2,320.6	
(g) Investments in joint venture	364.2	340.2	
(h) Financial assets	301.12	0-10.2	
(i) Investments	45,066.0	49,485.7	
(ii) Loans	5.8	7.	
(iii) Other financial assets	1,977.4		
		1,259.0	
(i) Deferred tax assets (Net)	36,411.5	28,967.2	
(j) Income tax assets (Net)	21,818.4	25,115.3	
(k) Other non-current assets	2,951.5	2,888.4	
Total non-current assets	354,526.1	347,848.9	
2) Current assets			
(a) Inventories	98,747.8	89,968.1	
(b) Financial assets	NA LINGUISTAN TO		
(i) Investments	84,739.3	76,339.4	
(ii) Trade receivables	122,007.5	105,928.9	
(iii) Cash and cash equivalents	42,962.5	45,082.5	
(iv) Bank balances other than (iii) above	10,648.3	5,251.0	
(v) Loans	1,849.2	1,699.	
(vi) Other financial assets	7,536.0	7,024.	
(c) Other current assets	21,538.2	18,855.	
(4) 5.11.51 (3.11.51)		70,000	
Total current assets	390,028.8	350,149.8	
TOTAL ASSETS	744,554.9	697,998.	
EQUITY AND LIABILITIES			
Equity			
Equity (a) Equity share capital	2,399.3		
Equity (a) Equity share capital (b) Other equity	528,780.0	477,712.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company	528,780.0 531,179.3	477,712. 480,112.	
Equity (a) Equity share capital (b) Other equity	528,780.0 531,179.3 32,461.8	477,712. 480,112. 30,548.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company	528,780.0 531,179.3	477,712. 480,112. 30,548.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity	528,780.0 531,179.3 32,461.8	477,712. 480,112. 30,548.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities	528,780.0 531,179.3 32,461.8	477,712. 480,112. 30,548.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities	528,780.0 531,179.3 32,461.8	477,712. 480,112. 30,548.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities	528,780.0 531,179.3 32,461.8	477,712 480,112 30,548 510,661	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings	528,780.0 531,179.3 32,461.8 563,641.1	477,712. 480,112. 30,548. 510,661.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities	528,780.0 531,179.3 32,461.8 563,641.1	477,712. 480,112. 30,548. 510,661. 2,299. 2,517.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities	528,780.0 531,179.3 32,461.8 563,641.1	477,712 480,112 30,548 510,661 2,299 2,517 161	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net)	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (b) Borrowings	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (2) Current liabilities (a) Financial liabilities (a) Financial liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (b) Borrowings	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (2) Current liabilities (i) Borrowings (ii) Lease liabilities (ii) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332 7,007 1,078 44,793 18,832	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (2) Current liabilities (i) Borrowings (ii) Lease liabilities (i) Borrowings (ii) Lease liabilities (b) Other financial liabilities (c) Current liabilities (d) Financial liabilities (e) Financial liabilities (f) Borrowings (f) Lease liabilities (f) Other financial liabilities (f) Other financial liabilities (f) Other financial liabilities (f) Other current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332 7,007 1,078 44,793 18,832 7,033	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities (iv) Other financial liabilities (iii) Trade payables (iv) Other financial liabilities (iv) Other current liabilities (v) Other current liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2 49,433.1	477,712. 480,112. 30,548. 510,661. 2,299. 2,517. 161. 3,690. 318. 6,344. 15,332. 7,007. 1,078. 44,793. 18,832. 7,033. 91,478.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (Net) (d) Other current liabilities (e) Provisions (f) Current tax liabilities (Net)	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2 49,433.1 2,876.1	477,712. 480,112. 30,548. 510,661. 2,299. 2,517. 161. 3,690. 318. 6,344. 15,332. 7,007. 1,078. 44,793. 18,832. 7,033. 91,478.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities (b) Other current liabilities (c) Provisions	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2 49,433.1	2,399. 477,712. 480,112. 30,548. 510,661. 2,299. 2,517. 161. 3,690. 318. 6,344. 15,332. 7,007. 1,078. 44,793. 18,832. 7,033. 91,478. 1,781.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Total non- current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (Net) (d) Other current liabilities (e) Provisions (f) Current tax liabilities (Net)	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2 49,433.1 2,876.1	477,712. 480,112. 30,548. 510,661. 2,299. 2,517. 161. 3,690. 318. 6,344. 15,332. 7,007. 1,078. 44,793. 18,832. 7,033. 91,478. 1,781.	
Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company Non-controlling interests Total equity Liabilities (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities Total non- current liabilities (2) Current liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (Net) Total current liabilities (iv) Other financial liabilities	528,780.0 531,179.3 32,461.8 563,641.1 4,470.8 42.8 3,572.7 322.2 5,490.4 13,898.9 38,069.1 1,115.4 51,087.6 16,707.4 7,726.2 49,433.1 2,876.1 167,014.9	477,712 480,112 30,548 510,661 2,299 2,517 161 3,690 318 6,344 15,332 7,007 1,078 44,793 18,832 7,033 91,478 1,781 172,005	





Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Unaudited Consolidated Cash Flow Statement for the Half Year ended September 30, 2022

(₹ in Million)

Particulars Half Year ended 30.08.2022 Unaudited 20.08.2022 Unaudited 30.08.2022 Unaudited 30.08.2022 Unaudited 30.08.2022 Unaudited 30.08.2022 Unaudited 40.097.3 Adjustments for: Depreciation and amortisation expense Half (pair) / loss on sale of write off / impairment of property, plant and equipment, other intangible assets and intangible assets under development 11,979.5 10,335.9		- Annual Control of the Control of t	(₹ in Million)
A. Cash flow from operating activities Pofit / (loss) before tax Adjustments for. Depreciation and amortisation expense Net (gain) / loss on sale / write off / impairment of property, plant and equipment, other interpiles assets and interpiles assets under development Finance costs Interest income Dividend income on investments Net (gain) / loss on sale of inflancial assets measured at fair value through profit or loss Net gain) / loss on sale of inflancial assets measured at fair value through profit or loss Net gain) / loss on sale of inflancial assets measured at fair value through profit or loss Net gain / loss on sale of inflancial assets measured at fair value through profit or loss Net gain) / loss on sale of inflancial assets measured at fair value through profit or loss Net gain / loss on sale of inflancial assets measured at fair value through profit or loss Net gain / loss on sale of inflancial assets measured at fair value through profit or loss Net gain / loss on sale of inflancial assets measured at fair value through other comprehensive income Provision / write off / (reversal) for doubtful trade receivables / advances 411.7 33.5 Sundry balances written back, net Effect of exchange rate changes Querting profit / (loss) before working capital: (Increase) / Decrease in inventories (Increase) / Decrease	Particulars	Half Year ended	Half Year ended
A. Cash flow from operating activities Profit / (loss) before tax Adjustments for: Depreciation and amortisation expense Net (gain) / loss on sale / write off / impairment of property, plant and equipment, other intangible assets and intangible assets under development Finance costs Interest income Dividend income on investments Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through other Operating in which is the loss of the sale of th			30.09.2021
Profit / (loss) before tax	A Cook flow for the state of th	Unaudited	Unaudited
Adjustments for. Depreciation and amortisation expense Net (gain) / loss on sale / write off / impairment of property, plant and equipment, other intangible assets and intangible assets under development Finance costs Interest income (1,216.2) (1,953.9) Dividend income on investments (1,216.2) (1,953.9) Dividend income on investments (1,216.2) (1,953.9) Dividend income on investments (1,216.2) (1,953.9) Net (gain) / loss arising on financial assets measured at fair value through profit or loss Net (gain) / loss on sale / off inancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Net (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Note (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Note (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Note (gain) / loss on sale of infrancial assets measured at fair value through profit or loss Note (gain) / loss on sale of investments Note (gain) / loss on sale of investments (gain) / loss of investments (gain) / loss of i	The state of the s	W. 5445	
Depreciation and amortisation expense 11,373.5 10,335.9 Net (pain) / Ioss on sale / Vivile off / Impairment of property, plant and equipment, other intangible assets and intangible assets under development (90.6) (1,216.2) Finance costs 330.8 710.4 Interest income (1,216.2) (1,953.9) Dividend income on investments (283.8) (1,739.0) Net (gain) / Ioss a risting on financial assets measured at fair value through profit or loss (394.9) (49.1) Net gain on sale of financial assets measured at fair value through profit or loss (394.9) (49.1) Comprehensive income (1,216.2) (1,216.2) Provision / write off / (reversal) for doubtful trade receivables / advances (112.6) (16.8) Effect of exchange rate changes (121.6) (16.8) Effect of exchange rate changes (2,306.6) (712.4) Operating profit / (loss) before working capital changes (3,306.2) Movements in working capital: (Increase) / Decrease in inventories (6,067.5) (3,233.8) (Increase) / Decrease in trade receivables (13,392.9) (9,286.1) (Increase) / Decrease in trade receivables (13,392.9) (9,286.1) (Increase) / (Decrease) in trade payables (4,755.4) (201.9) Increase / (Decrease) in trade payables (7,246.3 (1,474.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,475.4) (1,4	Want 77 To at the	46,972.7	40,907.3
Net (gain) / loss on sale / write off / impairment of property, plant and equipment, other intangible assets and intangible assets under development Finance costs Interest income (1,216,2) (1,953,9) Dividend income on investments Net (gain) / loss arising on financial assets measured at fair value through profit or loss Net (gain) / loss arising on financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through other comprehensive income Provision / write off / (reversal) for doubtful trade receivables / advances 411.7 33.5 Sundry balances written back, net Effect of exchange rate changes Qperating profit / (loss) before working capital changes Movements in working capital: (Increase) / Decrease in inventories (Increase) / Decrease in inventories (Increase) / Decrease in inventories (Increase) / Decrease in trade receivables (Increase) / Decrease in trade payables (Increase) / (Decrease) in provisions (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in other liabilities (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in other liabilities (Increase) / (Decrease) in other l			
Intrangible assets and intangible assets under development		A CONTRACTOR OF THE PARTY OF TH	
Interest income Dividend income on investments (1,216.2) (1,953.9) Dividend income on investments (1,216.2) (1,953.9) Dividend income on investments Net (gain) / loss arising on financial assets measured at fair value through profit or loss Net gain on sale of financial assets measured at fair value through profit or loss Net gain) / loss on sale of financial assets measured at fair value through other comprehensive income Provision / write off /(reversal) for doubful trade receivables / advances Provision / write off /(reversal) for doubful trade receivables / advances Sundry balances written back, net Effect of exchange rate changes Sundry balances written back, net Effect of exchange rate changes Cyao6.6 (712.4) Operating profit / (loss) before working capital changes Movements in working capital: (Increase) / Decrease in inventories (Increase) / Decrease in inventories (Increase) / Decrease in interate receivables (Increase) / Decrease in interate receivables (Increase) / Decrease in other assets (Increase) / Decrease in interate payables (Increase) / Decrease) in provisions (Increase) / Decrease) in trade payables (Increase) / Decrease) in trade payables (Increase) / Decrease) in trade payables	intangible assets and intangible assets under development	(90.6)	1,901.5
Interest income (1,216.2) (1,953.9) Dividend income on investments (263.8) (1,759.0) Dividend income on investments (263.8) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0) (1,759.0	Finance costs	330.8	710.4
Dividend income on investments Net (gain) / loss arising on financial assets measured at fair value through profit or loss Net gain on sale of financial assets measured at fair value through profit or loss Net gain on sale of financial assets measured at fair value through profit or loss Net (gain) / loss on sale of financial assets measured at fair value through other Comprehensive income Provision / write off // (reversal) for doubfful trade receivables / advances Sundry balances written back, net Effect of exchange rate changes Operating profit / (loss) before working capital changes Movements in working capital: (Increase) / Decrease in inventories (Increase) / Decrease in other assets (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in trade payables (Increase) / (Decrease) in other liabilities (Increase) / (Decrease) in provisions (Increase) / (Decrease) in other liabilities (Increase) / (Decrease) in trade payables (Increase) / (Decre	Interest income	(1,216.2)	(1,953.9)
Net (gain) / loss arising on financial assets measured at fair value through profit or loss 1,775.0 1,573.6 (84.1) Net (gain) / loss on sale of financial assets measured at fair value through other comprehensive income 49.6 (27.9) Comprehensive income 49.6 (27.9) Provision / write off /(reversal) for doubtful trade receivables / advances 411.7 33.5 Sundry balances written back, net (121.6) (16.8) Effect of exchange rate changes (123.6) (712.4) Operating profit / (loss) before working capital changes (3,366.6 (712.4) Operating profit / (loss) before working capital changes (5,067.5) 3,223.8 (Increase) / Decrease in inventories (6,067.5) 3,223.8 (Increase) / Decrease in trade receivables (13,992.9) (8,286.1) (Increase) / Decrease in trade receivables (13,992.9) (8,286.1) (Increase) / (Decrease) in trade payables (7,246.3 1,447.4 (1,247.4) Increase / (Decrease) in other assets (8,370.0) (5,003.3) Increase / (Decrease) in other instabilities (8,370.0) (41,851.2) 4,274.1 Cash generated / (used in) from operations (4,751.9) 45,447.1 Net Income tax (paid) / refund received (including interest on refunds) (4,539.2) (5,146.0) Net cash generated from / (used in) operating activities (A) (3,391.1) (40,271.1 B. Cash flow from investing activities (3,40.2) (3,391.1) (4,271.1 B. Cash flow from investing activities (3,360.6) (7,376.6) Proceeds from disposal of property, plant and equipment and other intangible assets and intangible assets under development) (19,40.2) (3,315.6) (7,376.6) Proceeds from sale of investments investment in subsidiaries and associates) (3,159.6) (7,376.6) (7,376.6) Proceeds from sale of investments investment in subsidiaries and associates) (5,378.3) (2,690.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (7,680.2) (Dividend income on investments	(263.8)	\$.4-4 D-51
Net (gain) / loss on sale of financial assets measured at fair value through other comprehensive income Provision / write off /(reversal) for doubtful trade receivables / advances ### 11.7 ### 33.5 ### Sundry balances written back, net ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (121.6) ### (12	Net (gain) / loss arising on financial assets measured at fair value through profit or loss	1,775.0	The state of the s
Comprehensive income	Net gain on sale of financial assets measured at fair value through profit or loss	(594.9)	(49.1)
Sundry balances written back, net (121.6) (16.8) Effect of exchange rate changes 2,306.6 (712.4)		49.6	(27.9)
Effect of exchange rate changes 2,306.6 (712.4)	Provision / write off /(reversal) for doubtful trade receivables / advances	411.7	33.5
Operating profit (loss) before working capital changes 51,538.8 50,963.1	Sundry balances written back, net	(121.6)	(16.8)
Movements in working capital: (Increase) / Decrease in inventories (Increase) / Decrease in trade receivables (Increase) / Decrease in trade receivables (Increase) / Decrease in other assets (Increase) / Decrease in other assets (Increase) / Decrease in other assets (Increase) / Decrease) in trade payables (Increase) / Decrease) in other liabilities (Increase) / Decrease) in provisions (Increase) / Decrease) / Decrease / De	Effect of exchange rate changes	2,306.6	(712.4)
(Increase) / Decrease in inventories (6,067.5) 3,223.8 (Increase) / Decrease in trade receivables (13,992.9) (8,286.1) (Increase) / Decrease in other assets (4,755.4) (201.9) Increase / (Decrease) in trade payables 7,246.3 1,447.4 Increase / (Decrease) in other labilities (6,870.0) (6,003.3) Increase / (Decrease) in provisions (41,851.2) 4,274.1 Cash generated / (used in) from operations (4,751.9) 45,417.1 Net cash generated from / (used in) operating activities (A) (9,391.1) 40,271.1 B. Cash flow from investing activities (10,760.2) (9,811.6) Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) (10,760.2) (9,811.6) Proceeds from disposal of property, plant and equipment and other intangible assets 119.4 232.9 Loans / inter corporate deposits given / placed - (76.8) Purchase of investments (includes investment in subsidiaries and associates) (93,159.6) (73,976.6) Proceeds from sale of investments 93,859.3 72,915.7 Bank balances not considered as cash and cash equivalents (5,378.3)	Operating profit / (loss) before working capital changes	61,538.8	50,963.1
(Increase) / Decrease in inventories (6,067.5) 3,223.8 (Increase) / Decrease in trade receivables (13,992.9) (8,286.1) (Increase) / Decrease in other assets (4,755.4) (201.9) Increase / (Decrease) in trade payables 7,246.3 1,447.4 Increase / (Decrease) in other labilities (6,870.0) (6,003.3) Increase / (Decrease) in provisions (41,851.2) 4,274.1 Cash generated / (used in) from operations (4,751.9) 45,417.1 Net cash generated from / (used in) operating activities (A) (9,391.1) 40,271.1 B. Cash flow from investing activities (10,760.2) (9,811.6) Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) (10,760.2) (9,811.6) Proceeds from disposal of property, plant and equipment and other intangible assets 119.4 232.9 Loans / inter corporate deposits given / placed - (76.8) Purchase of investments (includes investment in subsidiaries and associates) (93,159.6) (73,976.6) Proceeds from sale of investments 93,859.3 72,915.7 Bank balances not considered as cash and cash equivalents (5,378.3)	Movements in working capital:		
(Increase) / Decrease in trade receivables (Increase) / Decrease in other assets (Increase) / Decrease) in trade payables (Increase) / Decrease) in other liabilities (Increase) / (Increa		(6.067.5)	2 222 0
(Increase) / Decrease in other assets (Increase) / Decrease) in trade payables Increase / (Decrease) in trade payables Increase / (Decrease) in other liabilities (Increase) / (Decrease) in provisions (Increase) /	(Increase) / Decrease in trade receivables		
Increase / (Decrease) in trade payables		100000000000000000000000000000000000000	70.14x m 10.10
Increase / (Decrease) in other liabilities Increase / (Decrease) in provisions Increase / (Decrease) in providency Increase / (Decrease) in provisions Increase / (Decrease) in providency Incr		Total company	30-10-10-10-10-10-10-10-10-10-10-10-10-10
Increase / (Decrease) in provisions (41,851.2) 4,274.1 Cash generated / (used in) from operations Net Income tax (paid) / refund received (including interest on refunds) Net cash generated from / (used in) operating activities (A) (4,639.2) (5,146.0) Net cash generated from / (used in) operating activities (A) (9,391.1) 40,271.1 B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received			COMPANIAN
Cash generated / (used in) from operations Net Income tax (paid) / refund received (including interest on refunds) Net cash generated from / (used in) operating activities (A) B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received 176.6 176.6 176.6 176.6 176.6	The same of the sa		****
Net Income tax (paid) / refund received (including interest on refunds) Net cash generated from / (used in) operating activities (A) B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received Dividend received Dividend received (5,146.0) (9,391.1) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (10,760.2) (9,811.6) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,76.8) (10,760.2) (10,760.2) (10,760.2) (10,760.2) (10,760.2)			THE RESERVE OF THE PERSON OF T
Net cash generated from / (used in) operating activities (A) B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received Dividend received 1,046.2			WATER-WITH THE
B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received Payments for purchase of property, plant and equipment (including capital work-in-progress, other-in-progress, other-in			
Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2) (9,811.6) (10,760.2)	not out generated from (used in) operating activities (A)	(9,391.1)	40,271.1
other intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment and other intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received 1004.2			
intangible assets Loans / inter corporate deposits given / placed Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received 1,006.2 1,046.2	Payments for purchase of property, plant and equipment (including capital work-in-progress, other intangible assets and intangible assets under development)	(10,760.2)	(9,811.6)
Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received (93,159.6) (73,976.6) (73,976.6) (73,976.6) (2,690.2) (5,378.3) (2,690.2) 1,114.7 238.4 116.6 1,046.2		119.4	232.9
Purchase of investments (includes investment in subsidiaries and associates) Proceeds from sale of investments Bank balances not considered as cash and cash equivalents Fixed deposits / margin money placed Fixed deposits / margin money matured Disposal of subsidiary Interest received Dividend received Purchase of investments (93,159.6) (73,976.6) (73,976.6) (73,976.6) (2,690.2) (5,378.3) (2,690.2) 1,114.7 238.4 176.6 1,046.2	Loans / inter corporate deposits given / placed	. . .	(76.8)
Proceeds from sale of investments 93,859.3 72,915.7 Bank balances not considered as cash and cash equivalents (5,378.3) (2,690.2) Fixed deposits / margin money placed 1,000.0 1,114.7 Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received 176.6 1,046.2	Purchase of investments (includes investment in subsidiaries and associates)	(93,159.6)	
Fixed deposits / margin money placed (5,378.3) (2,690.2) Fixed deposits / margin money matured 1,000.0 1,114.7 Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received 176.6 1,046.2	Proceeds from sale of investments	150-00-00-00-00-00-00-00-00-00-00-00-00-0	and the second s
Fixed deposits / margin money placed (5,378.3) (2,690.2) Fixed deposits / margin money matured 1,000.0 1,114.7 Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received 176.6 1,046.2	Bank balances not considered as cash and cash equivalents		
Fixed deposits / margin money matured 1,000.0 1,114.7 Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received 176.6 1,046.2		(5,378.3)	(2,690.2)
Disposal of subsidiary - 238.4 Interest received 582.8 333.7 Dividend received 176.6 1,046.2	Fixed deposits / margin money matured	1,000.0	
Interest received 582.8 333.7 Dividend received 176.6 1,046.2	Disposal of subsidiary		The state of the s
Dividend received 1,046.2	Interest received	582.8	
N. A. S. A. C.	Dividend received	176.6	W. 1222 P. J.
	Net cash from / (used in) investing activities (B)	(13,560.0)	

SIGNED FOR IDENTIFICATION
BY

NS
SRBC&COLLP
MUMBAI



Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4 324 4324.

CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Unaudited Consolidated Cash Flow Statement for the Half Year ended September 30, 2022

(₹ in Million)

Particulars	Half Year ended 30.09.2022 Unaudited	Half Year ended 30.09.2021 Unaudited
C. Cash flow from financing activities Proceeds / (repayment) of borrowings and working capital loans (net)	27,461.1	(15,673.0
Repayment towards lease liabilities Payment for buy-back of equity shares held by non-controlling interests of subsidiaries Finance costs	(607.4) - (95.9)	(632.6 (1,843.0
Dividend payment to non-controlling interests Dividend paid	(5.9) (7,193.8)	(430.1 7.8 (4,812.1
Net cash from / (used in) financing activities (C)	19,558.1	(23,398.6
Net (decrease) / increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the period	(3,393.0) 45,082.5	6,198.5 62,730.5
Cash and cash equivalents transferred on sale of subsidiary / taken over on acquisition of subsidiary		(137.:
Effect of exchange differences on restatement of foreign currency cash and cash equivalents	1,273.0	686.6
Cash and cash equivalents at the end of the period	42,962.5	69,478.5





Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390012. Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324. CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com

Notes:

- These unaudited consolidated financial results relate to Sun Pharmaceutical Industries Limited (the 'Company'), its Subsidiaries (together the 'Group'), Joint Venture and Associates and are prepared by applying Ind AS 110 - "Consolidated Financial Statements", and Ind AS 28 - "Investments in Associates and Joint
- The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their 2 respective meetings held on November 01, 2022.
- The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as 3 amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- Exceptional items includes the following (Refer financial results of respective period for detailed information):
 - a) Results for the year ended March 31, 2022 and half year ended September 30, 2021 includes a charge of USD 60 Million (equivalent to ₹ 4,425.0 Million) on account of settlement by Taro Pharmaceuticals U.S.A., ("Taro") in respect of multi-jurisdiction civil antitrust matters. Further, during the year ended March 31, 2022, Sun Pharmaceutical Industries Inc. also entered into a settlement agreement with the Direct Purchaser Plaintiffs class ("DPPs") for an amount of USD 15.3 Million along with related legal charges of USD 5.5 Million (equivalent to ₹ 1,562.5 Million inclusive of legal charge).

Exceptional tax for the year ended March 31, 2022 is on account of recognition of deferred tax asset amounting to ₹ 272.7 Million arising out above settlement.

- b) Results for the year ended March 31, 2022 and half year ended September 30, 2021 includes a charge of ₹ 1,503.3 Million towards impairment of an acquired intangible asset under development. Further, the Group disposed off assets which were classified as assets held for sale as per the requirements of IND AS 105 and a write down of ₹ 382.4 Million was disclosed as an exceptional item.
- c) During the year ended March 31, 2022 the Company had incurred a one-time cost of ₹ 563.5 Million in relation to restructuring of operations in certain countries.
- d) Results for the year ended March 31, 2022 includes a charge of USD 485 Million along with its related legal charges of USD 8.3 Million (equivalent to ₹ 37,231.5 Million inclusive legal charges) towards settlement of alleged violation of antitrust laws.

Exceptional tax for the year ended March 31, 2022, is on account of recognition of deferred tax asset amounting to ₹ 4,897.5 Million arising out above settlement.

- e) Consequent to the settlement mentioned in 4(d) above, during the year ended March 31, 2022, the Company had written off MAT credit of ₹ 4,406.0 Million and disclosed the charge as an exceptional item.
- The Group has only one reportable segment namely 'Pharmaceuticals'.

Mumbai, November 01, 2022

- As part of the ongoing simplification of the group structure in India, the Board of Directors of the Company at its meeting held on May 30, 2022, approved the Scheme of Amalgamation for the merger of Wholly-owned Subsidiaries, Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited (collectively "Transferor Companies"), with Sun Pharmaceutical Industries Limited ("Transferee Company") with an appointed date of April 01, 2022 and / or such other date as may be approved by the National Company Law Tribunal pursuant to the provisions of Sections 230 to 232 of Companies Act, 2013 and other relevant provisions of the Companies Act, 2013 and rules framed thereunder.
- 7 On Febuary 28, 2022, our subsidiary company, Taro Pharmaceutical Industries Ltd., had acquired all of the outstanding capital stock of Galderma Holdings Inc. Proactiv YK; The Proactiv Company Corporation; and other assets of The Proactiv Company Sarl. Accordingly, the results for the quarter and half year ended September 30, 2022 are not comparable to the quarter and half year ended September 30, 2021 as presented.

Figures for previous periods have been regrouped / reclassified wherever considered necessary

SIGNED FOR IDENTIFICATION SRBC&COLLP

For and on behalf of the Board

Dilip S. Shanghvi Managing Director